A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05949749

Enrollment

1000

Registered

2023-07-18

Start date

2023-08-25

Completion date

2024-09-30

Last updated

2023-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma

Brief summary

Epstein-barr virus (EBV) infection is a necessary factor of nasopharyngeal carcinoma (NPC). The incidence of NPC in endemic regions reaches 24.60/100,000 people, far higher than that of the worldwide average. However, no EBV prophylactic vaccines is clinically available so far, which is largely hampered by the difficulties in selecting optimal vaccine design target out of 13 glycoproteins on the surface of EBV. In this study, we utilized humanized gp42-IgG antibodies to explore the dominant epitopes of gp42, one of the functional EBV glycoproteins during virus entry, to facilitate prophylactic vaccine design.

Interventions

DIAGNOSTIC_TESTEpitope exploration

Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Controls underwent physical examinations or primary NPC cases confirmed by pathology or cytology. * If cases, at stage I-IVB diagnosed by radiology according to AJCC/UICC 8th. * If cases, Karnofsky score (KFS)≥70, estimated survival span\>12 months. * If cases, no disordered of major organs is found; blood test, liver, and kidney functions are basically normal. * If cases, at least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1.

Exclusion criteria

* History of other malignant diseases. * History of severe systemic diseases or heart, lung, liver, or kidney disfunction. * History of severe neurological, metal, endocrine diseases. * History of HBV, HCV, HIV, TP, or TB infection. * If controls, physical examination reveals systemic diseases including malignant diseases. * If cases, incomplete blood and pathological sample data. * If cases, not receiving primary treatment in this facility. * Other individuals investigators find not suitable for the trial.

Design outcomes

Primary

Measure	Time frame	Description
Dominant gp42-IgG epitopes in cases	Baseline	Dominant gp42-IgG epitopes revealed by ELISA with non-competitive monoclonal humanized antibodies against gp42 will be compared between cases and controls.

Countries

China

Contacts

Primary ContactXiang-Wei Kong, Ph.D.

sorahick@qq.com0086-020-34071439

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026